Quality Assessment of Tracheal intubation without neuromuscular blocking drugs (Propofol+ Remifentanil) in obese patients: Pilot Study - OBEREM

niversity Hospital of Toulouse0 个研究点目标入组 60 人开始时间: 2021年5月11日最近更新: 2023年10月30日

试验速览

暂无简介。

•- Patient 18-60 years of age.
•- ASA class = 3
•- Patient with a BMI between 35 and 60 with indication for bariatric surgery, or BMI greater than 30 in case of bariatric surgery revision.
•- Patient scheduled for bariatric surgery (or repeat bariatric surgery) scheduled under general anesthesia with orotracheal intubation.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 60
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Full stomach patient defined by at least 1 of the following criteria:
•o Esophageal fibroscopy with visualized hiatal hernia.
•o Authenticated and treated gastroesophageal reflux.
•o Previously placed gastric band.
•- Known difficult orotracheal intubation (Cormack score = 3 (see Appendix 5)31).
•- Opioid or substituted drug addiction (Methadone, Buprenorphine...).
•- Chronic alcoholism (suspected or admitted).
•- Chronic treatment with an opiate.
•- Patient under guardianship, curatorship or under court protection.
•- Known hypersensitivity to propofol, sufentanil, remifentanil, soy or peanuts.
•- Severe renal or hepatic impairment.
•- Severe respiratory insufficiency.
•- Pregnant or breastfeeding woman.
•- Patient participating in another interventional research protocol that may interfere with study drugs

发起方

niversity Hospital of Toulouse